Log In
Print this Print this

TAK-580 (formerly MLN2480)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionOral selective pan-Raf kinase inhibitor
Molecular Target
Mechanism of ActionRaf inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat relapsed or refractory solid tumors; Treat solid tumors
Regulatory Designation
PartnerSunesis Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today